Login / Register The Most Trusted Name in Medical Education

Nursing

Elsevier's Office of CME offers a variety of courses for the nursing community.

Newborn image 1

Mosby's Essential Nursing CE: Newborn Series

Format: eLearning Activity

Mosby's Essential Nursing CE Newborn Series, sponsored by an educational grant from Mead Johnson Nutrition, is authored and peer reviewed by nurse experts. The four web-based, interactive, multimedia lessons are designed for perinatal nurses, and include a printable Lesson Notebook that is a detailed lesson outline for personal note taking. Elsevier provides the continuing education contact hours.* 

  1. Care of the Stable Newborn -  0.62 contact hours
  2. Newborn and Infant Nutrition -   0.71 contact hours
  3. Newborn Physiology -  0.54 contact hours
  4. Physical Assessment of the Newborn -  0.81 contact hours
*Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing. The provider number is #50-4681. Elsevier is provider approved by the California Board of Registered Nursing. The provider number is CEP 3257.

Click here to register and start earning free contact hours.

 

910701 116 x 144

Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Format: Webcast Series

This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making. 

Take Course »

 

Credits: Up to 1.00 AMA PRA Category 1 Credit(s)™
ASM 116x140

Addressing the Urgent Threat: Strategies for Combating Hard-To-Treat Bacterial Infections

Format: Webcast

In the United States, as many as 2 million patients are annually diagnosed with antibiotic-resistant Gram-positive or Gram-negative (GP/GN) infections. Unfortunately, the development of novel antibiotics has lagged dangerously behind the emergence of resistant infections, leaving these patients with limited treatment options. Recently, several novel antibiotics have been approved, and more are in the clinical pipeline, many of which have proven to be particularly effective in patients with harder-to-treat GP and/or GN pathogens. However, in the absence of the judicious use of these new antibiotics, acquired resistance to these new agents is inevitable. This archived symposium will provide participants with the opportunity to review the clinical utility of new and investigational antimicrobials while also focusing on strategies to promote careful, appropriate antibiotic utilization. Interactive patient case scenarios will allow clinicians to apply acquired knowledge of antibiotic use to real-world examples of treating patients with GP/GN infections.

Take Course »

Credits: 2.0 AMA PRA Category 1 Credits™
MEDX ONC 116x140

Patient-Centered Care for Genitourinary Cancers

Format: Webcast

Community oncologists are challenged to stay up to date with updated clinical practice guidelines on the personalization of treatments for genitourinary (GU) cancers, including prostate, urothelial, and renal cancers, combination/sequential therapies, emerging safety and efficacy data from ongoing studies of novel regimens, and strategies to facilitate patient engagement in order to improve patient outcomes. Clinicians need tools and resources to help educate their patients and empower them to participate in their care and make educated treatment choices. Advanced-stage GU cancers consists of a spectrum of disease that requires an integrated multidisciplinary approach supported by a uro-oncologic team. Therefore, it is critical to educate these clinicians on their roles within the multidisciplinary cancer care team and on the importance of effective communication with other members of the team to maximize patient outcomes.

Take Course »

Credits: 1.25 AMA PRA Category 1 Credits™ ; 1.2 Nursing contact hours; 1.25 ACPE hours
910687 116x140

Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary Care

Format: Webcast

This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.  

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™ or 1.00 Nursing Contact Hours
910734 116 x 140

CYSTIC FIBROSIS INTERVIEW WEBCAST SERIES

Format: Webcast

This activity includes eight 30-minute modules that bring learners up to date on all aspects of cystic fibrosis (CF) treatment and management. Dr. John P. Clancy interviews eight experts in the CF field, each with their own specialization. The individual modules will focus on different areas of CF care, ranging from newborn screening to long-term real world efficacy and safety data. Each module is worth approximately 0.5 CME/CNE credits.

 

Take Course »

 

Credits: 8 Modules Total - Approx. 0.5 AMA PRA Category 1 Credit™ / CNE Credits Each
Elsevier EHA 2017 Web 116x140 v3

EMERGING TARGETED THERAPIES IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Format: Medical Meeting Reporter

This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910726 116 x 140

Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, How, Why? A Roundtable Discussion

Format: Webcast

This activity is presented as a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to CF therapy in a case study based format. These discussions will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their CF therapy.

 

Take Course »

 

Credits: 1.50 AMA PRA Category 1 Credit(s)™
910742E 116 x 140

THE EMERGING ROLE OF CFTR COMBINATION REGIMENS IN IMPROVING OUTCOMES FOR PATIENTS WITH CYSTIC FIBROSIS

Format: Webcast

The content for this activity is based on the live, inter professional seminar titled, “The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis” that was presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, Indiana. This CME/CNE activity will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.

Take Course »

 

Credits: 1.50 AMA PRA Category 1 Credit(s)™ 1.50 Nursing Contact Hours
thumbnail

Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

Format: Webcast

Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.

Register»

Credits: 3.0 AMA PRA Category 1 Credits™